Efgartigimod following plasma exchange in the treatment of subjects with generalised myasthenia gravis: study protocol for a multicentre, three-arm, open-label study
BMJ Neurol Open. 2025 Aug 3;7(2):e001180. doi: 10.1136/bmjno-2025-001180. eCollection 2025. ABSTRACT INTRODUCTION: Myasthenia gravis (MG), an IgG-mediated autoimmune disorder targeting neuromuscular junctions, shows refractory in …